Regeneron Pharmaceuticals (REGN) FCF Margin (2009 - 2026)
Regeneron Pharmaceuticals' (REGN) quarterly FCF Margin came in at 23.53% in Q1 2026, down 341.0% year-on-year from 9.76% in Q1 2025, and down 0.88% quarter-over-quarter from 23.74% in Q4 2025.
Regeneron Pharmaceuticals (REGN) FCF Margin (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' FCF Margin history runs 18 years deep, the most recent figure standing at 23.53% for Q1 2026.
- On a quarterly basis, FCF Margin fell 341.0% year-over-year to 23.53% in Q1 2026; TTM through Mar 2026 was 27.57%, a 555.0% increase from a year earlier, with the FY2025 full-year figure at 28.45%, up 265.0% from the prior year.
- FCF Margin eased to 23.53% in Q1 2026 per REGN's latest filing, from 23.74% in the prior quarter.
- Across five years, FCF Margin topped out at 3919.8% in Q1 2022 and bottomed at 9.48% in Q2 2024.
- The 5-year median for FCF Margin is 26.94% (2025), against an average of 345.89%.
- Across the five-year window, FCF Margin jumped 389632 bps in 2022 and plunged 388219 bps in 2023, its largest moves.
- Year by year, FCF Margin stood at 1567.7% in 2022, then tumbled by 98 bps to 24.41% in 2023, then rose by 15 bps to 28.06% in 2024, then fell by 15 bps to 23.74% in 2025, then retreated by 1 bps to 23.53% in 2026.
- Per Business Quant, the three latest REGN FCF Margin figures stand at 23.53% (Q1 2026), 23.74% (Q4 2025), and 30.57% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 4.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.53% |
| Dec 31, 2025 | 23.74% |
| Sep 30, 2025 | 30.57% |
| Jun 30, 2025 | 32.51% |
| Mar 31, 2025 | 26.94% |
| Dec 31, 2024 | 28.06% |
| Sep 30, 2024 | 23.83% |
| Jun 30, 2024 | 9.48% |
| Mar 31, 2024 | 43.83% |
| Dec 31, 2023 | 24.41% |
| Sep 30, 2023 | 21.49% |
| Jun 30, 2023 | 35.63% |
| Mar 31, 2023 | 37.61% |
| Dec 31, 2022 | 1,567.70% |
| Sep 30, 2022 | 16.57% |
| Jun 30, 2022 | 14.38% |
| Mar 31, 2022 | 3,919.80% |
| Dec 31, 2021 | 44.78% |
| Sep 30, 2021 | 95.01% |
| Jun 30, 2021 | 8.52% |